Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 19, 2015
Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with obesity. Meant to inspire and encourage honest, open...
- Feb 13, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for BANZEL® (rufinamide) as an adjunctive treatment of seizures...
- Jan 20, 2015Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIVCard Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*
Eisai Inc. today announced the launch of a new savings card for BELVIQ® (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.**...
-
Jan 15, 2015•The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
Paris, January 15, 2015 – The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the...
- Dec 5, 2014-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters --
Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68th Annual American Epilepsy Society (AES) meeting, taking place in...
